Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart
3 Months : From Sep 2019 to Dec 2019
By Michael Dabaie
Roche Holding AG's (RO.EB, ROG.EB) Genentech said data was positive from the Phase III IMpower110 study evaluating Tecentriq in advanced non-squamous and squamous non-small cell lung cancer.
Genentech said the study looked at Tecentriq as a monotherapy in advanced non-squamous and squamous non-small cell lung cancer without ALK or EGFR mutations.
The study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer with high PD-L1 expression live longer compared with chemotherapy alone, Genentech said.
The company said it will share the data with health authorities globally, including the U.S. Food and Drug Administration and European Medicines Agency.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
September 27, 2019 11:05 ET (15:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.